Conduit Pharmaceuticals and AstraZeneca Partner on HK-4 Glucokinase Activators for Autoimmune Conditions
Friday, 9 August 2024, 16:18
Conduit Pharmaceuticals and AstraZeneca Collaboration
Conduit Pharmaceuticals Inc. has announced a significant partnership with AstraZeneca through an exclusive license agreement.
Details of the Agreement
- Licensed Products: HK-4 Glucokinase activators AZD1656 and AZD5658
- Target Indications: Autoimmune diseases and idiopathic male infertility
Clinical Developments
- Preclinical Studies: Positive results have been observed.
- Phase I Trials: Both products showed favorable outcomes.
- Next Steps: Initiation of Phase II clinical trials is planned.
Conclusion
This collaboration between Conduit Pharmaceuticals and AstraZeneca is expected to pave the way for groundbreaking treatments in autoimmune conditions and male infertility, potentially impacting the future of pharmaceutical advancements.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.